A B S T R A C T
Background and Objectives
Blood and blood product transfusion is a critical interventions for managing severe bleeding related to pregnancy and childbirth and plays a key role in reduction of maternal mortality. Given the high prevalence of anemia in pregnancy, multiple bleeding risk factors, and the necessity of optimizing the use of limited blood resources, this study investigated the frequency, usage patterns, and determinants of blood and blood product transfusion in pregnant women admitted to Hafez Hospital, in Shiraz.
Materials and Methods
This retrospective case-control study, reviewed the medical records of 1119 pregnant women hospitalized from 2017 to 2021. The case group comprised 527 women who received blood or blood products, while the control group included 592 women with no history of transfusion. Collected data included demographic characteristics, clinical and laboratory findings, pregnancy complications, and blood bank recods. Data were analyzed using independent t-test and Chi-square statistical tests with SPSS version 28.
Results
The most common indications for blood transfusion were low hemoglobin (54.46%), active bleeding (18.4%), and placental disorders (9.68%). Factors associated with transfusion included history of cesarean section ,, underlying diseases Particularly thalassemia minor , multiple pregnancy, high systolic blood pressure at admission, low hemoglobin, preeclampsia , fetal distress, premature rupture of membranes, and intrauterine growth restriction. The average number of transfused units was 2.15 for red blood cells (CI: 95% 1.97-2.33), 3.78 for plasma (CI: 95% 3.28-4.28), and 3.69 for platelets (CI: 95% 3.37-4.01). Among recipients, 98% received red blood cells, 10.17% platelets, 10.17% plasma, and 2.5% cryoprecipitate.
Conclusions
Anemia and bleeding were identified as the primary causes of blood transfusion during pregnancy. Enhancing systematic screening and timely treatment of anemia, strengthening prenatal care, reducing unnecessary cesarean sections, and developing standard protocols for obstetric complications may significantly reduce the need for blood and blood product transfusions.